Argos Therapeutics prices IPO below the range at $8, raising $45 million

Comment

Shutterstock photo

Argos Therapeutics, which is developing immunotherapies for the treatment of renal cell carcinoma and HIV, raised $45 million by offering 5.625 million shares (all primary) at $8. The company had originally filed to sell 4.25 million shares at a range of $13 to $15. Argos Therapeutics plans to list on the NASDAQ under the symbol "ARGS". Piper Jaffray, Stifel and JMP Securities acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com